乐普医疗：预计2025年净利润同比增长223.97%-385.95%

Core Viewpoint - The company expects a net profit of 800 million to 1.2 billion yuan for the fiscal year 2025, representing a year-on-year growth of 223.97% to 385.95% [1] Group 1: Financial Performance - The core business of cardiovascular interventional revenue is steadily increasing [1] - The retail channel inventory clearance in the pharmaceutical sector's formulation business is nearly complete, achieving double-digit revenue growth [1] - The traditional business foundation remains solid, providing stable profits and cash flow for the company [1] Group 2: Strategic Developments - The strategic emerging sectors, including innovative drugs and dermatology, have contributed to performance growth [1] - The net cash flow generated from operating activities has increased by approximately 95% [1]